
A FDA decision on HEB's Ampligen was originally expected by February 25, 2009, for the Company's submission of its Ampligen(r) NDA, which is designated as an Orphan Drug for the treatment of Chronic Fatigue Syndrome, which has no FDA approved treatments on the market. Ampligen(r) is also authorized for Emergency (compassionate) Cost Recovery Sales Authorization by the FDA and has a "promising" designation by the Agency on Health Research Quality (AHRQ): "Ampligen(r), an investigational drug that is not approved by the FDA, given intravenously to severely debilitated patients, yielded the most promising results." The extended user fee goal date is now May 25th, 2009.
May 26, 2009
Hemispherx Biopharma Announces Possible Brief Delay
The U.S. Food and Drug administration ("FDA") has advised the company that it may require up to 1-2 additional weeks
Now that the 1-2 weeks have past the company is now in a "limbo" state. We are waiting for the FDA decision on Ampligen and do not know when it will come. According to FDA statistics and the CEO Dr. Carter in a conference call Ampligen has a 80% chance of approval. It might be closer to 90% since this is a drug for which no other treatments exist. So the FDA wont be denying this drug because something works better, there is nothing else
Ampligen appears to be safe and effective. Here is a great article that separates the
fact from fiction.
Hemispherx BioPharma
One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103
Phone: (215) 988-0080
Fax: (215) 988-1739
Hemispherx Biopharma, Inc. -- Research & Development: Welcome to our Website Ampligen - Wikipedia, the free encyclopedia